Zyx Technology, Seoul National University sign MOU to support landscape design education
Zyx Technology, a Korean AI digital design platform company, signed a memorandum of understanding with the Department of Landscape Architecture and Regional System Engineering at Seoul National University's College of Agriculture and Life Sciences on June 10.
The signing ceremony was held at the university's Seoul campus, with Vice Dean Heo Jin-hoe of the College of Agriculture and Life Sciences, Zyx Technology Chairman Choi Jong-bok, and other key officials.
As part of the agreement, Zyx Technology will donate 150 educational licenses per year of its flagship computer-aided design software, ZyxCAD, for three years. The software will be used to support coursework and research in landscape design, with the goal of enhancing practical design training for students.
ZyxCAD is a general-purpose CAD program developed in Korea and listed in the national e-procurement system. It offers high compatibility with AutoCAD — supporting similar commands, shortcuts, file formats and LISP scripts — and features an intuitive interface with multi-CPU-based high-speed processing. The software also includes 'Works,' a utility suite with around 450 tools that streamline repetitive tasks and support complex design workflows.
'This collaboration with Seoul National University will be remembered as a meaningful case where Korea's top educational institution and domestic design software come together beyond the level of a single department,' said Zyx Technology Chairman Choi Jong-bok. 'We hope ZyxCAD will provide practical benefits to the department's advanced design education environment.'
Vice Dean Heo Jin-hoe said ZyxCAD will enhance hands-on learning and serve as a model for industrial-academic collaboration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.d08a9f94aea74f3da95329681a945806_T1.jpg&w=3840&q=100)
![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
20 minutes ago
- Korea Herald
[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline
BOSTON -- Korean biotech company GI Innovation showcased its next-generation growth strategy at Bio USA 2025 in Boston on Tuesday. Leading the presentation was Yun Nari, head of GI Innovation's clinical strategy, who introduced the company's new drug development pipeline and global business roadmap. A licensed pharmacist, Yun joined the company's board of directors in March and is expected to play a pivotal role in accelerating clinical decision-making, an essential function in GI Innovation's core business of clinical-stage drug development. A key highlight was the unveiling of GI-128, a novel immuno-oncology candidate that leverages macrophage engagement, an emerging target in next-generation cancer therapies. The company also spotlighted its trispecific antibody pipeline, designed to surpass the current generation of aPD-(L)1/VEGF bispecific antibodies, which are gaining significant traction in the global oncology space. 'This year's Bio USA is a premier platform that brings together leading global investors and pharmaceutical companies,' said Jang Myoung-ho, CEO and founder of GI Innovation. 'It presented the perfect opportunity to demonstrate the competitiveness of our pipeline and global expansion strategy. We plan to actively explore a variety of partnership opportunities, including technology licensing, co-development deals and strategic investments.' Meanwhile, the growing interest in aPD-(L)1/VEGF bispecific antibodies in the immuno-oncology sector has led to a surge in high-value deals. Bristol Myers Squibb recently entered into a licensing agreement with German biotech firm BioNTech, paying an upfront sum of approximately $1.5 billion, with the total deal valued at around $11.1 billion. Likewise, Merck & Co. signed a deal last year with China-based LaNova Medicines, worth $588 million upfront and up to $2.7 billion in milestone payments. Building on this trend, GI Innovation's trispecific antibody platform integrates the company's proprietary aPD-L1 antibody, a VEGF antibody and a macrophage engager into a single molecule. The design aims to overcome the therapeutic limitations of bispecific antibodies by stimulating a more robust immune response within the tumor microenvironment, the company explained.
![[Photo News] LG's US headquarters doubles as science and tech hub](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.629f6e07c53f4441ab62aff43d8c4dec_T1.jpg&w=3840&q=100)
Korea Herald
an hour ago
- Korea Herald
[Photo News] LG's US headquarters doubles as science and tech hub
LG Electronics has been operating the LG Inspiration Lab at its North American headquarters in Englewood Cliffs, New Jersey, showcasing interactive exhibitions featuring OLED displays, robots and EV simulators. The lab allows local students to experience cutting-edge technology, drawing over 4,000 visitors last year, quadrupling from 1,000 in 2023. The site also hosts college students studying the Korean language and foreign diplomats for tech briefings and discussions about cross-border partnerships.
Korea Herald
3 hours ago
- Korea Herald
Seoul, Beijing discuss China's technical barriers to trade in cosmetics, bio-health
South Korea and China discussed measures to reduce technical barriers to trade between the two countries in cosmetics, bio-health and other sectors Wednesday, Seoul's industry ministry said, in a move to help improve the trade environment for local exporters. In their ninth TBT committee meeting held in Beijing, the Korean side addressed key challenges local exporters face regarding China's regulations on the approval of cosmetics and medical devices, as well as standards on Korean red ginseng products, according to the Ministry of Trade, Industry and Energy. Seoul also asked Beijing to allow more Korean certification institutions to issue the China Compulsory Certificate, a mandatory product certification for exports to China, while seeking to learn more about Beijing's pilot testing of a carbon footprint certification system. "The government will continue its efforts to identify and address technical regulation challenges Korean companies face when exporting to China, the largest export destination for the country last year," said Seo Young-jin, director general of the bureau of technical regulatory policy at the Korean Agency for Technology and Standards under the ministry. South Korea and China have been holding regular TBT committee meetings under their bilateral free trade agreement since 2015, when the FTA came into force. (Yonhap)
